Quince Therapeutics (QNCX) Common Equity (2018 - 2026)

Quince Therapeutics has reported Common Equity for 9 years, with the latest figure at -$35.3 million in Q2 2026.

• On a quarterly basis, Common Equity fell 400.99% year-over-year to -$35.3 million in Q2 2026; TTM through Jun 2026 was -$35.3 million, a 400.99% decrease from a year earlier, with the FY2025 full-year figure at -$35.7 million, down 218.47% from the prior year.
• Common Equity was -$35.3 million for Q2 2026 at Quince Therapeutics, down from $15.7 million in the prior quarter.
• The five-year high for Common Equity was $111.5 million in Q2 2022, with the low at -$35.7 million in Q4 2025.
• Average Common Equity over 5 years is $52.3 million, with a median of $60.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Common Equity fell 15.17% in 2022, then plunged 400.99% in 2026.
• Over 5 years, Common Equity stood at $100.6 million in 2022, then declined by 15.42% to $85.1 million in 2023, then sank by 64.57% to $30.1 million in 2024, then sank by 218.47% to -$35.7 million in 2025, then gained by 1.09% to -$35.3 million in 2026.
• The last three Common Equity figures came in at -$35.3 million (Q2 2026), $15.7 million (Q1 2026), and -$35.7 million (Q4 2025), per Business Quant data.